anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Multidrug-resistant Acinetobacter baumannii (MDRAB) is an important pathogen that causes nosocomial infections and is resistant to almost all antibiotics, including carbapenems. Cefiderocol is a novel siderophore cephalosporin active against a broad spectrum of gram-negative bacteria. However, the susceptibility of MDRAB to cefiderocol has not yet been reported in Japan. In this study, we measured the minimum inhibitory concentrations (MICs) of antibiotics including cefiderocol against MDRAB clinical isolates collected during a nosocomial outbreak between 2009 and 2010 at the Teikyo University Hospital in Japan. We found that all 10 MDRAB clinical isolates tested were susceptible to cefiderocol, with an MIC range of 0.12 to 1 μg/mL. All the isolates also exhibited resistance to ampicillin-sulbactam and an intermediate resistance to colistin, whereas nine of them were susceptible to tigecycline. DNA sequencing revealed that all strains harbored an OXA-51-like carbapenemase, a major cause of carbapenem resistance in A. baumannii in Japan. In conclusion, this study showed that the cefiderocol susceptibility of MDRAB clinical isolates in Japan was equivalent to that to colistin or tigecycline, and thus cefiderocol is a potential treatment option for MDRAB infections.
PURPOSE:To obtain a new compound capable of forming a thermotropic liquid crystal in water disperse system, soluble in almost all solvents, having good dispersibility to water, exhibiting very excellent lubricating properties and useful as a emulsifier, a lubricating agent, a liquid forming agent, etc. CONSTITUTION:A compound of formula I (R<1> is 16-36C branched alkyl; R<2> to R<4> are H or 16-36C branched alkyl), e.g. 1mol isostearyl ether adduct of pentaerythritol of formula II. This compound is obtained by reacting pentaerythritol or its branched alkyl ether with a branched alkyl halide of the formula R<1>X (X is halogen) (preferably branched alkyl bromide such as isostearyl bromide or heptyldecyl bromide) in the presence of a basic substance (preferably NaOH, etc.), preferably at 80-150 deg.C. Furthermore, this reaction is preferably carried out by dissolving or dispersing the compound of formula II in an organic solvent such as methanol and then adding a branched alkyl halide thereto while removing water content.
Recent studies have established the moment-to-moment turnover of the blood-oxygen-level-dependent signal (TBOLD) at resting state as a key measure of local cortical brain function. Here, we sought to extend that line of research by evaluating TBOLD in 70 cortical areas with respect to corresponding brain volume, age, and sex across the lifespan in 1,344 healthy participants including 633 from the Human Connectome Project (HCP)-Development cohort (294 males and 339 females, age range 8-21 yr) and 711 healthy participants from HCP-Aging cohort (316 males and 395 females, 36-90 yr old). In both groups, we found that 1) TBOLD increased with age, 2) volume decreased with age, and 3) TBOLD and volume were highly significantly negatively correlated, independent of age. The inverse association between TBOLD and volume was documented in nearly all 70 brain areas and for both sexes, with slightly stronger associations documented for males. The strong correspondence between TBOLD and volume across age and sex suggests a common influence such as chronic neuroinflammation contributing to reduced cortical volume and increased TBOLD across the lifespan.NEW & NOTEWORTHY We report a significant negative association between resting functional magnetic resonance imaging (fMRI) blood-oxygen-level-dependent (BOLD) signal turnover (TBOLD) and cortical gray matter volume across the lifespan, such that TBOLD increased whereas volume decreased. We attribute this association to a hypothesized chronic, low-grade neuroinflammation, probably induced by various neurotropic pathogens, including human herpes viruses known to be dormant in the brain in a latent state and reactivated by stress, fever, and various environmental exposures, such as ultraviolet light.
The invention discloses a bee venom liniment for treating prostatitis. The bee venom liniment comprises the following materials, by weight, 40-60 parts of bee venom, 5-10 parts of propolis, 1-5 parts of pearls, 20-30 parts of plant extract and 15-30 parts of lanolin oil. The preparation method comprises the following steps: pearls are ground to 100-150 meshes, the pearl powder, the plant extract, bee venom, propolis and lanolin oil are mixed according to the above weight parts and stirred uniformly, and the finished product is obtained. The bee venom liniment has advantages of good stability, uniform coating and good spreadability. Human body trial experiment results prove that the bee venom liniment is safe, has no stimulation or optical allergenicity to skins and can treat prostatitis effectively. The bee venom liniment has advantages of rapid onset, obvious effects and safe usage, and raises the cure rate of prostatitis.
The prescribed dose for all patients will be 5040 cGy in 28 fractions. Patients will receive external beam treatment once a day, five days a week for approximately five and a half weeks.
An anti-coagulant enzyme is prepared from the venom of Ancistrodon Rhodostoma (the Malayan Pit Viper), by adsorption on, and stepwise elution from a weakly basic anion exchange resin. The enzyme is characterized by the following properties: (1) it is proteinaceous, and colourless when pure; (2) it is absorbable on weakly basic anion exchange materials (e.g. diethylaminoethyl- and triethylaminoethyl-cellulose); (3) it is soluble in physiological saline; (4) it has an electrophoretic mobility of 3.9 x 10-5 volts/cm/sec. in 0.1 M phosphate buffer at pH 7.0; (5) it has a M.W. not greater than 40,000 in monomeric form in the ultracentrifuge; (6) it has a sedimentation coefficient of 3.4 svedburgs at a concentration of 4.86 mgs/ml.; (7) it has a partial specific volume at this concentration of approximately 0.7; (8) it has thrombin-like defibrinating activity, but since the fibrin does not form a clot, it is anti-coagulant in vivo; (9) it is not inhibited by 1 x 10-3 molar diiso propyl fluorophosphate within 5 minutes.  The enzyme is prepared by adsorption of the venom on a column of one of the aforesaid anion exchangers, and eluted with buffers of stepwise increasing molarity, at pH 6.0, the enzyme coming off with 0.09 to 0.1 molar buffer.  The eluate may be freeze-dried or sterilized and rendered isotonic with physiological saline for use in pharmaceutical compositions (see Divisions A5-A6).  A method for the assay of its activity, by determination of its effect on the clotting time of blood, is described.ALSO:Anti-coagulant pharmaceutical compositions contain a purified, enzyme-containing preparation derived from the venom of Ancistrodon Rhodostoma (the Malayan Pit Viper) by chromatographic fractionation, which is substantially free from proteolytic enzymes which cause tissue and vascular necrosis.  The preparation is prepared by chromatographing the venom on a column of weakly basic (i.e. sufficiently weak not to cause protein denaturation) anion exchange material, such as dialkylamino alkyl polysaccharides, e.g. DEAE and TEAE cellulose; the adsorbed materials are eluted step-wise with buffer of increasing molarity, the active material coming off with about 0.09 to 0.1 M buffer at pH 6.0.  The solution may then be freeze-dried, or made isotonic with physiological saline and sterilized to provide an injectable composition.  This may be filled into ampules, or the reconstituted freeze-dried powder used, in unit dosage forms for intramuscular or intravenous injection.  The active enzyme may be obtained in the pure state, and is characterised in terms of its properties (see Division C3); it has thrombin-like de-fibrinating properties, but the fibrin produced does not form clots, and the enzyme is hence anticoagulant in vivo.
AIMS: To assess agreement of bacterial culture results from samples taken from nasal discharge, the nasal cavity and nasal biopsy from dogs and cats with nasal disease.
METHODS: Nineteen dogs and 21 cats with different nasal diseases (chronic rhinitis, n = 30; neoplasia, n = 7; sinonasal aspergillosis, n = 3) were prospectively enrolled in the study. Nasal swabs were taken bilaterally from nasal discharge at the nares, the nasal cavity, and one nasal mucosal biopsy per side. All samples were subjected to aerobic bacterial culture. Kappa statistics were used to evaluate agreement for the most prevalent bacterial species between sampling sites.
RESULTS: A positive culture result for at least one bacterial species was detected in 80% of samples from nasal discharge/nares, 92% of nasal cavity samples, and 75% of biopsy samples. The mean agreement between the three sampling sites for positive vs. negative culture results was never greater than moderate and the precision of the estimates of agreement varied widely.The most frequently isolated bacterial species in dogs were Staphylococcus pseudintermedius, Staphylococcus spp. and Streptococcus spp. In cats, Pasteurella spp. and Staphylococcus felis were the bacterial species cultured most frequently.For the most prevalent cultured species, Staphylococcus spp., mean agreement between sites was never greater than fair and the precision again varied widely.
CONCLUSION: This study indicates that bacterial culture results in feline and canine nasal disease are site-specific and there was no evidence from this study for consistency between sites within a patient for many bacterial species. Consequently, if bacterial culture results from nasal swabs are used to guide therapeutic antimicrobial choice, different treatments may be selected depending on the site of culture. As a consequence, there is no evidence from this study that nasal bacterial cultures should be recommended as a routine diagnostic measure.
Indigo naturalis extract in oil (INEO) was applied to the fingernails of one bilateral hand (experimental group) twice daily for the first 12 weeks. INEO was applied to all affected nails on both hands twice daily for another 12 weeks.
PROBLEM TO BE SOLVED: To obtain a bath agent composition containing a cationic polymer, giving such a slimy skin touch as if taking a natural hot spring, giving a moist touch to a skin after taking the bath, enabling to experience a real famous hot spring, and excellent in solubility, when used. SOLUTION: This bath agent composition contains a cationized polymer having a particle diameter of <=250μm in such an amount as giving a concentration of 1-50ppm in bath hot water. When the bath agent composition is used e.g. in an amount of 50g per 200 liter of bath hot water, the cationic polymer is added in an amount of 0.4-20wt.% based on the whole amount of the bath agent. The average mol.wt. of the cationic polymer is preferably <=2000000 from the aspect of touch and solubility, and the cationic polymer includes a cationic cellulose and cationic Cyamoposis Gum. When the bath agent composition is charged into bath hot water, a real hot spring feeling can immediately be experienced.
BACKGROUND: Portal vein stent placement is used for portal vein stenosis. However, reports on postpancreatic surgery cases are rare. Whether antithrombotic therapy should be administered remains controversial. In this paper, the authors reviewed current data to evaluate the influence of antithrombosis on stent patency after pancreatic surgery.
MATERIALS AND METHODS: This systematic review and meta-analysis compared studies in which patients did or did not receive antithrombotic therapy after portal vein stent placement. The authors compared patency after stent placement and complication rate.
RESULTS: There were 22 ( n =207) studies in which patients received antithrombotic therapy and 8 ( n =61) in which patients did not receive therapy. Antithrombotic agents, such as aspirin, clopidogrel, heparin, and warfarin, were used. The overall patency rates were similar between the groups (79.2% in the antithrombosis group vs. 88.0% in the nonantithrombosis group). Subgroup analyses included those for the etiology of stenosis, types of antithrombotic agents, acute or chronic stenosis, and causes of stent stenosis. None revealed a significant difference between the patency rates in the antithrombosis and nonantithrombosis groups. However, bleeding complications only occurred in patients who received antithrombotic therapy.
CONCLUSION: There is no significant benefit of antithrombotic therapy after portal vein stent placement following pancreatic surgery. Antithrombotic therapy should be performed with caution because it may cause complications, such as bleeding.
Studies at clinically relevant doses in humans have demonstrated that fluoxetine blocks the uptake of serotonin into human platelets. Studies in animals also suggest that fluoxetine is a much more potent uptake inhibitor of serotonin than of norepinephrine.

Antagonism of muscarinic, histaminergic, and α1-adrenergic receptors has been hypothesized to be associated with various anticholinergic, sedative, and cardiovascular effects of classical tricyclic antidepressant (TCA) drugs. Fluoxetine binds to these and other membrane receptors from brain tissue much less potently in vitro than do the tricyclic drugs.

Enantiomers — Fluoxetine is a racemic mixture (50/50) of R-fluoxetine and S-fluoxetine enantiomers. In animal models, both enantiomers are specific and potent serotonin uptake inhibitors with essentially equivalent pharmacologic activity. The S-fluoxetine enantiomer is eliminated more slowly and is the predominant enantiomer present in plasma at steady state.
In this group, the volunteer will start with sham TMS, will be the same parameters was used in experimental group, however, it will be performed using two coils, one connected to the magnetic stimulator, away from the patient's scalp and another uncoupled from the stimulator and positioned in the same way as in real stimulation. After, the volunteer will be submitted to 50 minutes of physical therapy protocol.
Participants in the waitlist-control group will be required to continue their usual physical activities. At the end of 10 weeks, they will also receive access to FIT-TEENS intervention.
Objective The effect of Rikkunshito, a Japanese herbal Kampo medicine, on chemotherapy-induced nausea and vomiting (CINV) has been evaluated in several small prospective studies, with mixed results. We retrospectively evaluated the antiemetic effects of Rikkunshito in patients undergoing cisplatin-based chemotherapy using a large-scale database in Japan. Methods The Diagnosis Procedure Combination inpatient database from July 2010 to March 2019 was used to compare adult patients with malignant tumors who had received Rikkunshito on or before the day of cisplatin administration (Rikkunshito group) and those who had not (control group). Antiemetics on days 2 and 3 and days 4 and beyond following cisplatin administration were used as surrogate outcomes for CINV. Patient backgrounds were adjusted using the stabilized inverse probability of treatment weighting, and outcomes were compared using univariable regression models. Results We identified 669 and 123,378 patients in the Rikkunshito and control groups, respectively. There were significantly fewer patients using intravenous 5-HT3-receptor antagonists in the Rikkunshito group (odds ratio, 0.38; 95% confidence interval, 0.16-0.87; p=0.023) on days 2 and 3 of cisplatin-based chemotherapy. Conclusion The reduced use of antiemetics on day 2 and beyond of cisplatin administration suggested a beneficial effect of Rikkunshito in palliating the symptoms of CINV.
Each point was stimulated with a laser (Luminex Laser Therapy System: Medical Laser Systems, Branford, CT) set at 5 joules/cm2 (J/cm2) in continuous mode for 0.10 seconds. Based on various studies, a minimum of 4 J/cm2 produces an improved circulatory effect.
Part B. Participants with diabetes mellitus will receive a single oral dose of LY3108743 in dose escalation cohorts in up to 2 of 3 study periods.
Risk Summary

There are no data on the presence of baloxavir marboxil in human milk, the effects on the breastfed infant, or the effects on milk production. Baloxavir and its related metabolites were present in the milk of lactating rats (see Data). The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for XOFLUZA and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition.

Data

In a lactation study, baloxavir and its related metabolites were excreted in the milk of lactating rats administered baloxavir marboxil (1 mg/kg) on postpartum/lactation day 11, with peak milk concentration approximately 5 times that of maternal plasma concentrations occurring 2 hours post-dose. No effects of baloxavir marboxil on growth and postnatal development were observed in nursing pups at the highest oral dose tested in rats. Maternal systemic exposure was approximately 5 times the baloxavir exposure in humans at the MRHD.
<P>PROBLEM TO BE SOLVED: To provide a right/back classifying device capable of classifying secant locks randomly directed right and back to at least the right side and the back side.  <P>SOLUTION: Ridge projections 2 across the route of the secant locks are disposed on a main surface 1 used when the secant locks m slide and move. The ridge projections have a cross section shape allowing engagement of the secants. The main surface is set to be a downward slope, the ridge projections are downwardly tilted, feed vibration is applied to the main surface and the ridge projections, and the secant locks are moved while being made to climb over the ridge projections. Thus, the secants of the back-side secant locks m2 engage with the ridge projections 2, move on the projections, and are discharged from a back-side outlet 5. The right-side secant locks m1 move as they are and are discharged from an outlet 4.  <P>COPYRIGHT: (C)2003,JPO
This first in human study consists of 2 parts: a) The dose escalation part and b) The dose expansion part. This is an openlabel (all participants know the identity of the intervention), multicenter (more than one study site) study to evaluate the safety, establish a recommended Phase 2 dose (RP2D), and to determine the preliminary efficacy of duvortuxizumab in participants with relapsed or refractory B cell malignancies. The dose escalation part of the trial (Part 1) will be comprised of 3 different patient groups based on disease indication: Group 1 (DLBCL, FL, MCL); Group 2 (CLL); Group 3 (ALL). The duvortuxizumab dosing will be done on biweekly and weekly basis. Duvortuxizumab weekly escalating dosing will be investigated. Dose escalation will begin with Group 1 and will initially follow an accelerated dose titration design, followed by a traditional 3+3 design. At each dose escalation level the treatment of the second participant should be initiated after at least 72 hours of observation after the start of the first duvortuxizumab dose of the first participant. Dose escalation in Groups 2 and 3 will follow a 3+3 design and will begin after the initial dose level in Group 1 is deemed safe. Participants \[Group 1 (DLBCL, FL, MCL), Group 2 (CLL) Group 3 (ALL)\] are enrolled into cohorts of increasing dose levels of duvortuxizumab administered in 28 day treatment cycles. Up to 3 RP2Ds may be determined in Part 1 (one RP2D for Group 1, one RP2D for Group 2, and one RP2D for Group 3). In the cohort expansion part of the trial (Part 2), participants with relapsed or refractory B cell malignancies (DLBCL, FL, MCL, CLL and ALL) will be enrolled according to tumor type in up to 5 cohorts and receive duvortuxizumab at the RP2D determined in Part 1 for their disease type. The study consists of 3 periods: Screening period (up to 28 days prior to the first dose of study drug); Treatment period \[first dose of study drug until the End of Treatment Visit (within 30 days after the last dose)\]; and follow up period \[End of Treatment Visit and continue until death, lost to follow up, consent withdrawal, or study end (as determined by the sponsor), whichever occurs first\]. Number of participants who achieve an overall response in each Dose Expansion cohort will be evaluated primarily. Participants' safety will be monitored throughout the study.
Compositions and methods for treating or preventing respiratory disorders and airway inflammation in an animal are disclosed. In one embodiment, the respiratory disorder is asthma. In one embodiment, the airway inflammation is asthma-related. In one embodiment, the respiratory disorder is cystic fibrosis. The method comprises administering an electrolyzed saline solution to the animal. In one embodiment, the electrolyzed saline solution comprises about 0.1 ppm to about 100 ppm ozone and one or more active species selected from the group consisting of: about 5 ppm to about 300 ppm of at least one active chlorine species, about 0.1 ppm to about 300 ppm of at least one active oxygen species, about 5 ppm to about 300 ppm active hydrogen species, and combinations thereof. A mouse model of cystic fibrosis and methods of screening pharmaceutical agents are also provided.
The invention discloses oligomeric nucleic acid for inhibiting CD44 genes. The oligomeric nucleic acid is double-chain RNA (ribonucleic acid). Basic groups of the oligomeric nucleic acid constitute: (1) oligomeric nucleic acid having more than 70% of homology and shown in the SEQ. ID NO.18, (2) oligomeric nucleic acid having more than 50% of sequence homology and reversely and complementarily matched with the oligomeric nucleic acid sequence in (1) and (3) a double-chain structure formed after the oligomeric nucleic acid in (1) and the oligomeric nucleic acid in (2) are annealed. The invention discloses DNA containing the oligomeric nucleic acid, a carrier, composition and an application of the DNA, the carrier or the composition. The oligomeric nucleic acid has a remarkable inhibition function on CD44, can inhibit inflammation in an animal experiment and is a promising inflammation treatment medicine.
Biodegradable controlled release microspheres for the prolonged administration of a local anesthetic agent, and a method for the manufacture thereof are disclosed. The microspheres are formed of a biodegradable polymer degrading significantly within a month, with at least 50% of the polymer degrading into non-toxic residues which are removed by the body within a two week period. Useful polymers include polyanhydrides, polylactic acid-glycolic acid copolymers and polyorthoesters containing a catalyst; polylactic acid-glycolic acid copolymers are preferred. Local anesthetics are incorporated into the polymer using a method that yields a uniform dispersion, preferably solvent casting. Prolonged release is obtained by incorporation of a glucocorticoid into the polymeric matrix or by co-administration of the glucocorticoid with the microspheres. The type of anesthetic and the quantity are selected based on the known pharmaceutical properties of these compounds.
The selected patients will receive 1g of ferric carboxymaltose applied intravenously after dilution in 100ml of crystalline solution. the infusion time will be around 15 minutes realized at the moinhos the vento infusion center.